Alphatec Holdings Inc (ATEC) saw a significant decline of 19.38% as it crossed below its 5-day SMA, reflecting investor concerns following recent news.
The company has entered into a strategic partnership with Theradaptive, securing exclusive U.S. commercial rights to the OsteoAdapt® bone graft. This partnership is expected to deliver long-term value through upfront and milestone payments along with a perpetual royalty structure. OsteoAdapt leverages AMP2™ protein technology and is currently undergoing clinical trials for spinal and dental applications, having received three FDA Breakthrough Device Designations, indicating its potential to revolutionize the bone regeneration market.
Despite the recent stock decline, the strategic partnership positions Alphatec to capitalize on a significant market opportunity in the U.S. spine surgery market, which exceeds $10 billion annually. The ongoing clinical trials and the expected commercialization of OsteoAdapt could drive future revenue growth.
Wall Street analysts forecast ATEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATEC is 24.55 USD with a low forecast of 19.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast ATEC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATEC is 24.55 USD with a low forecast of 19.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 15.260
Low
19.00
Averages
24.55
High
28.00
Current: 15.260
Low
19.00
Averages
24.55
High
28.00
TD Cowen
Buy
downgrade
$27 -> $20
2026-01-26
New
Reason
TD Cowen
Price Target
$27 -> $20
AI Analysis
2026-01-26
New
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Alphatec to $20 from $27 and keeps a Buy rating on the shares following a transfer of coverage. The firm sees the company's "growth vectors" as not being fully appreciated in Street expectations. This creates potential upside to estimates, the analyst tells investors in a research note.
Barclays
Overweight
maintain
$23 -> $27
2026-01-07
Reason
Barclays
Price Target
$23 -> $27
2026-01-07
maintain
Overweight
Reason
Barclays raised the firm's price target on Alphatec to $27 from $23 and keeps an Overweight rating on the shares. The firm cites the recent increase in comparable stocks for the target multiple boost.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ATEC
Unlock Now
Freedom Capital
Keith Hinton
Buy
initiated
$25
2025-12-10
Reason
Freedom Capital
Keith Hinton
Price Target
$25
2025-12-10
initiated
Buy
Reason
Freedom Capital analyst Keith Hinton initiated coverage of Alphatec with a Buy rating and $25 price target. The firm thinks the pure-play spine medtech company can continue to grow well above the market as the company leverages its differentiated strategy, lateral portfolio and growing scale to take share, the analyst tells investors.
Morgan Stanley
Equal Weight
maintain
$21 -> $23
2025-12-02
Reason
Morgan Stanley
Price Target
$21 -> $23
2025-12-02
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Alphatec to $23 from $21 and keeps an Equal Weight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
About ATEC
Alphatec Holdings, Inc., through its wholly owned subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S. and SafeOp Surgical, Inc., is a medical device company. The Company is focused on the design, development, and advancement of technology for better surgical treatment of spine disorders. The Company's Organic Innovation Machine is focused on developing new approaches that integrate with its expanding Alpha InformatiX (AIX) Platform to better inform surgery and safely and reproducibly achieve the goals of spine surgery. Its technologies include AIX, positioners, access systems, implants and fixation systems, and biologics. Its AIX product platform comprises its EOS imaging system and VEA alignment mobile application, its SafeOp Neural InformatiX System and its navigation-enabled robotics platform (Valence). It has developed approach-specific patient positioning systems that integrate with its other access systems, providing for a more rigid construct and enhanced reproducibility.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
